May 10 |
ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...
|
May 9 |
ALX Oncology reports Q1 results
|
May 9 |
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
May 7 |
ALX Oncology Appoints Allison Dillon as Chief Business Officer
|
Apr 30 |
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
|
Apr 24 |
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
|
Apr 18 |
ALX Oncology: Trying To Justify The Hype
|
Apr 15 |
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
|
Apr 11 |
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
|
Apr 9 |
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
|